Suvretta Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Suvretta Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,370	Closed	-$2.53M	–	99
2025 Q1	$2.53M	Buy	+9,370	New	+$2.41M	0.09%	73
2024 Q4	–	Sell	-13,824	Closed	-$3.8M	–	99
2024 Q3	$3.8M	Sell	13,824 -23,800	-63%	-$6.2M	0.12%	69
2024 Q2	$9.14M	Buy	37,624 +4,964	+15%	+$784K	0.34%	52
2024 Q1	$4.88M	Buy	32,660 +22,800	+231%	+$3.8M	0.18%	63
2023 Q4	$1.89M	Buy	+9,860	New	+$1.68M	0.09%	65

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Suvretta Capital Management's ALNY Position: Q2 2025 in Review

Suvretta Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 9,370 shares — an estimated $2.53M sold.

Suvretta Capital Management first reported a position in ALNY in Q4 2023 and held it in 5 quarters. The position peaked at $9.14M in Q2 2024. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

Suvretta Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Suvretta Capital Management sold 9,370 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $2.53M.
Suvretta Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 5 quarters.
Suvretta Capital Management's Alnylam Pharmaceuticals position peaked at $9.14M in Q2 2024.
654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Suvretta Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.